Sandor Victor 4

What Happened

• Sandor Victor, a director of Prelude Therapeutics (PRLD), was granted a derivative option award for 38,000 shares on 2026-06-09. The Form 4 reports the acquisition price as $0.00 per share (total reported value $0) — this is a grant of rights to acquire shares, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (timely filing).
• Transaction type: Award/Grant (derivative) for 38,000 shares at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The option award will fully vest upon the earlier of (a) the issuer’s next annual stockholder meeting or (b) the one‑year anniversary of the grant date, provided the reporting person continues service on each vesting date.
• No immediate sale or cashless exercise reported; this is a compensation grant rather than a liquidity event.

Context

• This is a compensation-related option award that vests subject to continued service and a timing condition; it does not represent an open-market purchase or sale and does not indicate immediate cash proceeds. Grants like this are common for directors and should be monitored for future vesting, exercise, or sale filings that could change ownership levels.